Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goldstone, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstone, A. H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 9:S83-S85, 1998
© 1998 European Society for Medical Oncology

Reviews

The case for and against high-dose therapy with stem cell rescue for early poor prognosis Hodgkin's disease in first remission

A. H. Goldstone

Department of Clinical Haemalology, UCL Hospitals London. UK

Correspondence to: Dr. A. H. Goldstone Department of Clinical Haematology University College Hospital Grafton Way London WCIE6AUUK

After 10 years we are still not clear whether dose escalation with stem cell transplantation isrelevant for some patients with poor prognosis Hodgkin's disease in first remission. Some of the problems relating to the controversy relate to the fact that the definition of high risk Hodgkin's disease in terms of prognostic factors is only now in 1998 being delineated properly. It is also possible that some of the dose escalation in lymphoma has taken place without an adequate amount of conventional therapy beforehand. It may be possible that dose escalation should be added to an adequate amount of conventional chemotherapy not integrated in a conventional regimen thus shortening it. Newer studies from the German Hodgkin's Disease Study Group, i.e. HD9, may be suggesting that conventional chemotherapy is producing good results in poor prognosis patients and thus negating the need for dose escalation and stem cell transplantation.

first remission, Hodgkin's disease, stem cell transplant


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.